Pregabalin carries real cardiovascular risks that heart patients need to take seriously. It is not contraindicated for people with heart disease, but the FDA specifically warns that it should be used with caution in patients with heart failure, particularly those with more advanced disease. The concerns center on fluid retention, weight gain, and emerging evidence linking long-term use to higher rates of heart failure and other cardiovascular events.
How Pregabalin Affects the Heart
Pregabalin works by binding to voltage-gated calcium channels in the brain, which is how it reduces nerve pain and seizures. But these same calcium channels also exist in heart muscle. By blocking calcium flow in the heart, pregabalin can interfere with normal cardiac function, including how the heart contracts and conducts electrical signals.
In clinical trials, pregabalin prolonged the PR interval (the time it takes for electrical signals to travel through the upper chambers of the heart) by 3 to 6 milliseconds at doses of 300 mg per day or higher. For most people, this small change doesn’t cause problems. It wasn’t linked to dangerous heart rhythm disturbances in trials. However, in overdose situations, heart block has been reported in post-marketing data, which suggests the effect on cardiac conduction can become clinically meaningful at high exposures.
The Heart Failure Connection
The most significant concern for heart patients is the association between pregabalin and heart failure. A large study published in JAMA Network Open tracked over 114,000 person-years of follow-up and found that pregabalin users developed heart failure at a rate of 18.2 per 1,000 person-years, compared to 12.5 per 1,000 person-years for those taking gabapentin, a closely related medication. That translates to a 48% higher risk of heart failure with pregabalin.
The risk was even steeper for people who already had cardiovascular disease. In that subgroup, pregabalin was associated with an 85% higher risk of heart failure compared to gabapentin. Women and white patients also showed elevated risk in the same analysis. Post-marketing surveillance has noted a growing number of heart failure reports specifically tied to pregabalin, a pattern not seen with gabapentin.
A separate study using a large national database of patients with diabetic neuropathy found that long-term pregabalin use was associated with increased risk across multiple cardiovascular outcomes over five years: a 20% higher risk of heart failure, 29% higher risk of heart attack, 26% higher risk of stroke, 35% higher risk of peripheral vascular disease, and 57% higher risk of deep vein thrombosis. These are observational findings, meaning they show associations rather than proof of direct causation, but the consistency across multiple outcomes and studies is notable.
Fluid Retention and Swelling
About 15% of people taking pregabalin develop peripheral edema, which is swelling in the hands, legs, and feet caused by fluid buildup. For someone without heart problems, this is uncomfortable but usually manageable. For someone with an already weakened heart, extra fluid in the body forces the heart to work harder and can trigger or worsen heart failure symptoms like shortness of breath, fatigue, and further swelling.
The risk of fluid retention increases when pregabalin is combined with certain other medications. The FDA label specifically flags thiazolidinediones (a class of diabetes medication) as a concern because they also cause fluid retention and weight gain. Combining them with pregabalin could compound the problem. Research on psychotropic drug-related edema has identified pregabalin as carrying a particularly high risk of causing severe swelling.
Weight Gain Adds to the Burden
Pregabalin commonly causes weight gain, and this matters for heart patients. In controlled trials lasting up to 14 weeks, 9% of pregabalin users gained 7% or more of their body weight, compared to just 2% of those on placebo. Among diabetic patients specifically, the average weight gain was 1.6 kg over the trial period. For those who stayed on the medication for two years or longer, the average gain climbed to 5.2 kg (about 11.5 pounds).
For people managing heart failure or other cardiovascular conditions, added weight increases the workload on the heart. The FDA label explicitly states that weight gain “can also be a serious problem for people with heart problems.” Combined with fluid retention, this creates a dual burden that can destabilize previously controlled heart conditions.
What the FDA Label Actually Says
Pregabalin is not formally contraindicated in heart disease. The only listed contraindication is a known allergy to the drug. However, the FDA label includes several specific cautions for cardiac patients. It advises that there is limited safety data on patients with moderate to severe heart failure (NYHA Class III or IV) and that the drug should be used with caution in these individuals. The patient-facing information warns people to tell their doctor if they “have heart problems including heart failure” before starting pregabalin.
Kidney Function Changes the Equation
Many heart patients also have reduced kidney function, and this matters because pregabalin is cleared almost entirely by the kidneys. When the kidneys work less efficiently, pregabalin builds up in the body, intensifying all of its effects, including fluid retention and cardiac risks. Dose reductions are essential based on how well the kidneys are filtering.
For people with moderately reduced kidney function (creatinine clearance of 30 to 59 mL/min), the maximum dose drops roughly in half. For those with more severe impairment (clearance of 15 to 29 mL/min), the dose drops further still. People on dialysis need supplemental doses only after each session. If your kidney function has declined and your pregabalin dose hasn’t been adjusted, you may be accumulating more of the drug than intended, raising your risk of side effects including cardiac ones.
How It Compares to Gabapentin
Gabapentin belongs to the same drug class and treats many of the same conditions, but the cardiovascular data looks consistently more favorable. In the JAMA Network Open study, gabapentin had a meaningfully lower rate of new heart failure. Post-marketing surveillance has also noted that the pattern of heart failure reports seen with pregabalin has not appeared with gabapentin. Pregabalin is a more potent calcium channel blocker than gabapentin, which likely explains the difference. For heart patients who need this type of medication, gabapentin may represent a lower-risk alternative worth discussing.
Practical Considerations for Heart Patients
If you have heart disease and are currently taking pregabalin, the key things to monitor are your weight, ankle and leg swelling, and any new or worsening shortness of breath. Rapid weight gain over a few days usually signals fluid retention rather than fat gain, and this is especially important to catch early in someone with a cardiac history. Keeping a daily weight log can help you and your doctor spot trends before they become emergencies.
If you’re considering starting pregabalin, the decision depends heavily on the severity of your heart condition, your kidney function, what other medications you take, and what alternatives exist for the condition being treated. The risks are not the same for someone with well-controlled mild heart disease as they are for someone with advanced heart failure. Dose matters too: many of the cardiac effects, including PR prolongation and edema rates, increase at higher doses.